AACHEN, Germany, July 8, 2026 /PRNewswire/ -- Grünenthal announced today that its investigational compound tegacorat (GRM-01) received Orphan Drug and Rare Pediatric Disease Designations from the US Food and Drug Administration (FDA) for the treatment of Duchenne muscular dystrophy (DMD)....
Hence then, the article about grunenthal receives fda orphan drug and rare pediatric disease designations for tegacorat for the treatment of duchenne muscular dystrophy was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Grünenthal receives FDA Orphan Drug and Rare Pediatric Disease Designations for Tegacorat for the Treatment of Duchenne Muscular Dystrophy )
Also on site :
- Garth Brooks’ Daughter Receives Backlash for Her Dolly Parton Tribute
- 1975 Folk Rock Hit, Inspired by Bob Dylan’s Marriage, Ranked Among ‘Best Rock Love Songs’ of All Time
- Dollywood CEO Makes One Thing Clear About the Park After Dolly Parton’s Death